2007
DOI: 10.1016/j.bjps.2007.02.012
|View full text |Cite
|
Sign up to set email alerts
|

Orbital exenteration for advanced periorbital skin cancers: 20 years experience

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

11
50
0
8

Year Published

2010
2010
2021
2021

Publication Types

Select...
4
3

Relationship

0
7

Authors

Journals

citations
Cited by 84 publications
(69 citation statements)
references
References 40 publications
11
50
0
8
Order By: Relevance
“…When clinically appropriate, selecting surgical reconstruction techniques, such as split thickness skin grafts, that do not impair the ability to detect recurrence may be advantageous. 36 For patients with periorbital BCC and cutaneous SCC who are not surgical candidates due to unresectable disease, multifocal malignancies, multiple medical comorbities, or for whom orbital exenteration is not accepted, targeted systemic therapy is another treatment option which warrants consideration as well as further investigation. Vismodegib (Erivedge), a hedgehog pathway inhibitor approved by for the treatment of metastatic and locally advanced BCC, has been shown to produce either a complete or partial response in 30-60 percent of patients with metastatic or locally advanced BCC, 37 and has also been used as neoadjuvant therapy for patients with orbital invasion to make globe-sparing surgical resection possible.…”
Section: Discussionmentioning
confidence: 99%
“…When clinically appropriate, selecting surgical reconstruction techniques, such as split thickness skin grafts, that do not impair the ability to detect recurrence may be advantageous. 36 For patients with periorbital BCC and cutaneous SCC who are not surgical candidates due to unresectable disease, multifocal malignancies, multiple medical comorbities, or for whom orbital exenteration is not accepted, targeted systemic therapy is another treatment option which warrants consideration as well as further investigation. Vismodegib (Erivedge), a hedgehog pathway inhibitor approved by for the treatment of metastatic and locally advanced BCC, has been shown to produce either a complete or partial response in 30-60 percent of patients with metastatic or locally advanced BCC, 37 and has also been used as neoadjuvant therapy for patients with orbital invasion to make globe-sparing surgical resection possible.…”
Section: Discussionmentioning
confidence: 99%
“…[7][8][9][10] These techniques offer rapid healing and provide for the application of prosthesis. However they are not suitable in cases where tumour recurrence is likely.…”
Section: Discussionmentioning
confidence: 99%
“…(2,9,10) Other studies from tropical regions show a preponderance of SCC as indication for OE 3 . In this study most of our patients had neglected ocular surface SCC.…”
Section: 11mentioning
confidence: 99%
See 2 more Smart Citations